BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Option Update: Teva Pharmaceutical volatility flat; shares sell off]]>http://www.bloggingstocks.com/2008/07/07/option-update-teva-pharmaceutical-volatility-flat-shares-sell/http://www.bloggingstocks.com/2008/07/07/option-update-teva-pharmaceutical-volatility-flat-shares-sell/http://www.bloggingstocks.com/2008/07/07/option-update-teva-pharmaceutical-volatility-flat-shares-sell/#commentsFiled under: ,

Teva Pharmaceutical (NASDAQ: TEVA) is recently down $3.05 to $44.15 in pre-open trading after announcing that late-stage, top-line results showed the 40mg dose of its multiple sclerosis drug Copaxone was not more effective in reducing the relapse rate than the 20mg dose already approved.

TEVA overall option implied volatility of 25 is near its 26-week average according to Track Data, suggesting non-directional movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Option Update: Teva Pharmaceutical volatility flat; shares sell off originally appeared on BloggingStocks on Mon, 07 Jul 2008 09:44:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>copaxoneinthenewsoption implied volatilityOptionImpliedVolatilitytevaMon, 07 Jul 2008 09:44:00 EST<![CDATA[Teva tries again with oral MS drug]]>http://www.bloggingstocks.com/2007/11/07/teva-tries-again-with-oral-ms-drug/http://www.bloggingstocks.com/2007/11/07/teva-tries-again-with-oral-ms-drug/http://www.bloggingstocks.com/2007/11/07/teva-tries-again-with-oral-ms-drug/#commentsFiled under: ,

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), the largest generic drug maker in the world, has begun enrolling patients in the Phase III clinical trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis. The plan is to have 1,000 patients in the trial, which will last between 2-3 years.

Teva already produces Copaxone for the treatment of MS, but has twice tried unsuccessfully in the past to produce an oral drug. This time it is teaming up with the Swedish drug company Active Biotech to trial the oral drug.

If successful, along with Copaxone, Teva will be the clear leader in the fight to treat MS. For the sake of all who suffer from MS, let's hope the third time is a charm, and Teva has success with the oral drug.

Aaron Katsman is the lead Portfolio Manager and Managing Director of America Israel Investment Associates, LLC. and Senior Editor of IsraelNewsletter.com. Author holds a position in TEVA.

Teva tries again with oral MS drug originally appeared on BloggingStocks on Wed, 07 Nov 2007 14:35:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>copaxonegeneric drugsGenericDrugsinthenewsmstevaWed, 07 Nov 2007 14:35:00 EST<![CDATA[Teva hit with a triple-firm downgrade after posting triple-digit growth]]>http://www.bloggingstocks.com/2006/11/08/teva-hit-with-a-triple-firm-downgrade-after-posting-triple-digit/http://www.bloggingstocks.com/2006/11/08/teva-hit-with-a-triple-firm-downgrade-after-posting-triple-digit/http://www.bloggingstocks.com/2006/11/08/teva-hit-with-a-triple-firm-downgrade-after-posting-triple-digit/#commentsFiled under: , , , ,

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) was downgraded by three firms today, after posting third quarter net income growth of 127%.

JP Morgan downgraded Teva from Overweight to Neutral and Wachovia downgraded it from Outperform to Market Perform. Goldman Sachs only reduced target price on TEVA to $40 from $42 while maintaining Neutral rating. All firms cite 2007 as being a problem. Some focus on the competition front, others on growth catalyst while others yet are wary of the management change.

While it's true that net income surged 127% to $606 million, or 74 cents per share and beat analysts expectations, sales actually came below analysts' estimates. Net sales for the third quarter of 2006 increased 74% to $2,286 million, compared to $1,317 million in the third quarter of 2005. Lower than expected tax rate contributed to the strong net income, while several exclusive generic drugs pushed gross margins to 55%. The company expects gross margins to return to the 47%-50% range in 2007 as exclusivity on these drugs end.

IVAX, another generics manufacturer which Teva had acquired back in January in a deal worth $7.9 billion, seems to have been successfully integrated into the company's operations, according to the CEO, "realizing tremendous synergies."

So despite the strong quarter, analysts believe that what drove the results this quarter will not be present in 2007.

TEVA shares, which opened down 2%, are now trading flat, no doubt benefiting from the overall market rally at the moment (2:30 p.m.).

Teva hit with a triple-firm downgrade after posting triple-digit growth originally appeared on BloggingStocks on Wed, 08 Nov 2006 15:40:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>copaxoneivaxtevaWed, 08 Nov 2006 15:40:00 EST